56 related articles for article (PubMed ID: 19277418)
1. Vascular events in Korean patients with myeloproliferative neoplasms and their relationship to JAK2 mutation.
Bang SM; Lee JS; Ahn JY; Lee JH; Hyun MS; Kim BS; Park MR; Chi HS; Kim HY; Kim HJ; Lee MH; Kim H; Won JH; Yoon HJ; Oh DY; Nam EM; Bae SH; Kim BK;
Thromb Haemost; 2009 Mar; 101(3):547-51. PubMed ID: 19277418
[TBL] [Abstract][Full Text] [Related]
2. Iron is a modifier of the phenotypes of JAK2-mutant myeloproliferative neoplasms.
Stetka J; Usart M; Kubovcakova L; Rai S; Rao TN; Sutter J; Hao-Shen H; Dirnhofer S; Geier F; Bader MS; Passweg JR; Manolova V; Dürrenberger F; Ahmed N; Schroeder T; Ganz T; Nemeth E; Silvestri L; Nai A; Camaschella C; Skoda RC
Blood; 2023 Apr; 141(17):2127-2140. PubMed ID: 36758212
[TBL] [Abstract][Full Text] [Related]
3. Features of immune mediated diseases in JAK2 (V617F)-positive myeloproliferative neoplasms and the potential therapeutic role of JAK inhibitors.
Álvarez-Reguera C; Prieto-Peña D; Herrero-Morant A; Sánchez-Bilbao L; Batlle-López A; Fernández-Luis S; Paz-Gandiaga N; Blanco R
Eur J Intern Med; 2024 May; 123():102-106. PubMed ID: 38044168
[TBL] [Abstract][Full Text] [Related]
4. Guidelines for the management of myeloproliferative neoplasms.
Choi CW; Bang SM; Jang S; Jung CW; Kim HJ; Kim HY; Kim SJ; Kim YK; Park J; Won JH
Korean J Intern Med; 2015 Nov; 30(6):771-88. PubMed ID: 26552452
[TBL] [Abstract][Full Text] [Related]
5. The involvement of Galectins in the modulation of the JAK/STAT pathway in myeloproliferative neoplasia.
Koopmans SM; Bot FJ; Schouten HC; Janssen J; van Marion AM
Am J Blood Res; 2012; 2(2):119-27. PubMed ID: 22762031
[TBL] [Abstract][Full Text] [Related]
6. Combination of ruxolitinib with ABT-737 exhibits synergistic effects in cells carrying concurrent JAK2
Yuan J; Song J; Chen C; Lv X; Bai J; Yang J; Zhou Y
Invest New Drugs; 2022 Dec; 40(6):1194-1205. PubMed ID: 36044173
[TBL] [Abstract][Full Text] [Related]
7. Myeloproliferative and thrombotic burden and treatment outcome of thrombocythemia and polycythemia patients.
Michiels JJ
World J Crit Care Med; 2015 Aug; 4(3):230-9. PubMed ID: 26261774
[TBL] [Abstract][Full Text] [Related]
8. Distinct clinico-molecular arterial and venous thrombosis scores for myeloproliferative neoplasms risk stratification.
Pasquer H; Daltro de Oliveira R; Vasseur L; Soret-Dulphy J; Maslah N; Zhao LP; Marcault C; Cazaux M; Gauthier N; Verger E; Parquet N; Vainchenker W; Raffoux E; Ugo V; Luque Paz D; Roy L; Lambert WC; Ianotto JC; Lippert E; Giraudier S; Cassinat B; Kiladjian JJ; Benajiba L
Leukemia; 2024 Feb; 38(2):326-339. PubMed ID: 38148396
[TBL] [Abstract][Full Text] [Related]
9. Risk of thrombosis, hemorrhage and leukemic transformation in patients with myeloproliferative neoplasms: A nationwide longitudinal cohort study.
Hur JY; Choi N; Choi JH; Kim J; Won YW
Thromb Res; 2024 Apr; 236():209-219. PubMed ID: 38461615
[TBL] [Abstract][Full Text] [Related]
10. Clinical features associated with thrombotic events in children with myeloproliferative neoplasms.
Shimano KA; Vanderpoel V; Stone H; Resar L; Kucine N
Am J Hematol; 2022 Sep; 97(9):E353-E355. PubMed ID: 35751861
[TBL] [Abstract][Full Text] [Related]
11. Systematic analysis of copper, zinc, and selenium levels in JAK2 V617F-positive myeloproliferative neoplasms.
Shivarov V; Tsvetkova G; Atanasova B; Genova MP; Ivanova I; Hadjiev E; Ivanova M
Ann Hematol; 2024 Jun; 103(6):2177-2179. PubMed ID: 38233569
[No Abstract] [Full Text] [Related]
12. Loss of Dnmt3a increased self-renewal and resistance to pegIFNα in JAK2-V617F-positive myeloproliferative neoplasms.
Usart M; Stetka J; Luque Paz D; Hansen N; Kimmerlin Q; Almeida Fonseca T; Lock M; Kubovcakova L; Karjalainen R; Hao-Shen H; Börsch A; El Taher A; Schulz J; Leroux JC; Dirnhofer S; Skoda RC
Blood; 2024 Mar; ():. PubMed ID: 38493481
[TBL] [Abstract][Full Text] [Related]
13. Laboratory-developed Droplet Digital PCR Assay for Quantification of the JAK2
Liu Y; Han C; Li J; Xu S; Xiao Z; Guo Z; Rao S; Yao Y
Glob Med Genet; 2024 Jun; 11(2):132-141. PubMed ID: 38585044
[TBL] [Abstract][Full Text] [Related]
14. JAK2 V617F and the evolving paradigm of polycythemia vera.
Means RT
Korean J Hematol; 2010 Jun; 45(2):90-4. PubMed ID: 21120186
[TBL] [Abstract][Full Text] [Related]
15. Myeloproliferative Neoplasm Symptom Assessment Total Symptom Score (MPN-SAF TSS) in Chronic Myeloproliferative Neoplasms, Related with Genetic Burden, and Thrombosis.
Ümit E; Baysal M; Kırkızlar HO; Demir AM
Turk J Haematol; 2024 May; ():. PubMed ID: 38801033
[TBL] [Abstract][Full Text] [Related]
16. Secondary Acute Myeloid Leukemia in a One-Year-Old Girl Diagnosed with JAK2-V617F Mutation Positive Myeloproliferative Neoplasm.
Woods GM; Bajwa RP; Kahwash SB; Guinipero T
Case Rep Med; 2014; 2014():473297. PubMed ID: 24744787
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular risk in a contemporary cohort of patients with myeloproliferative neoplasms'.
Mehta D; Alimam S; McLornan DP; Henry JA; Ahmed S; Ghosh AK; Tyebally S; Walker JM; Patel R; Amerikanou R; O'Nions J; Wilson AJ; Lambert J; Sekhar M; Chen D
Curr Res Transl Med; 2024 Mar; 72(1):103420. PubMed ID: 38262189
[TBL] [Abstract][Full Text] [Related]
18. Serum Has Higher Proportion of Janus Kinase 2 V617F Mutation Compared to Paired EDTA-Whole Blood Sample: A Model for Somatic Mutation Quantification Using qPCR and the 2
Barra GB; Santa Rita TH; Almeida ALSC; Jácomo RH; Nery LFA
Diagnostics (Basel); 2020 Mar; 10(3):. PubMed ID: 32178286
[TBL] [Abstract][Full Text] [Related]
19. Myelofibrosis 2012: it's complicated.
Hubbeling HG; Frank DM; Hexner EO
Ther Adv Hematol; 2012 Jun; 3(3):131-46. PubMed ID: 23556120
[TBL] [Abstract][Full Text] [Related]
20. Predictors of clinical outcome in myeloproliferative neoplasm, unclassifiable: A Bone Marrow Pathology Group study.
Crane GM; Geyer JT; Thakral B; Wang SA; Wool GD; Li KD; Davis AR; Boiocchi L; Bosler D; Bueso-Ramos CE; Arber DA; George TI; Bagg A; Hasserjian RP; Orazi A; Hsi ED; Rogers HJ
Am J Clin Pathol; 2024 Apr; ():. PubMed ID: 38597584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
